Environmental Sustainability in Biopharmaceutical Facility Design

About the Author

Strategic Solutions Leader

Arcadis

William Whitford, MS, is the Life Science Strategic Solutions Leader for the Arcadis Strategic Consulting Team, supporting innovative therapeutic developments and biomanufacturing processes. An invited...

Emily Heffernan, PE

US Director, New Process Technology

Arcadis US

Emily is a process engineer, specializing in biological process and facility design. Working in the life sciences for over 20 years, she has gained expertise...

Aoife Kelly

Chartered Senior Architect

DPS Group

Aoife Kelly, MRIAI, is a Chartered Senior Architect with DPS Group, and a member of the Royal Institute of Architects of Ireland (RIAI). She has...

Technical

Selection Criteria for Pharmaceutical Containment Equipment

1 March 2024

Pharmaceutical manufacturing facilities produce a variety of products, including highly potent products that require safety measures to prevent adverse health effects on patients and operators. To ensure safety, these facilities use containment equipment to minimize the risk of contamination. This article presents criteria for selecting containment equipment, considering both...

Technical

Electrochemical Techniques for Onsite Surface Qualification

1 March 2024

Pharmaceutical critical utilities are typically built of 316L stainless steel; nevertheless, surface degradation has been reported due to the occurrence of different phenomena. This article aims to explain how field electrochemical techniques using a portable tool can be an effective method for surface inspection, qualification, and monitoring. The surface finish assessment considered...

Technical

Using Industry Survey Data to Shape Cell Therapy Facility Design

1 January 2024

Cell therapies have been used to treat thousands of patients worldwide ever since the CAR T cell medication Kymriah was the first cell therapy approved by the FDA in 2017. Yet significant manufacturing challenges continue to hamper patient access to life-saving cell therapies, particularly the high cost of these treatments. Kymriah can cost as much as $475,000 per dose and an allogeneic...

About the Author

Facilities of the Future: Meeting the Demands of Breakthrough Therapeutics

Emerging Leader Hacker to GAMPer in 10 Weeks

New Initiative Seeks to Back up ICHs Harmonization Mission

Data Science-Assisted Biopharmaceutical Tech Transfer and Process Characterization

Entering a New Era of Innovation and Collaboration With the Focus on the Workforce of the Future

Q&A with ISPE Foundation Professional Development Grant Recipient Silas Tamufor

Related Articles